![]() |
Douglas Loe, Leede Jones Gable(1/13/23) |
||
|
|||
| |||
Clive Maund, CliveMaund.com(12/21/22) |
|||
|
|||
| |||
![]() |
Dr. André Uddin, Research Capital Corporation(11/30/22) |
||
|
|||
| |||
Clive Maund, CliveMaund.com(10/24/22) |
|||
|
|||
Clive Maund, CliveMaund.com(10/16/22) |
|||
|
|||
Clive Maund, CliveMaund.com(9/27/22) |
|||
|
|||
| |||
| |||
| |||
| |||
|
Gerard Adams, President & CEO – National Inflation Association | |
![]() |
Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable |
Clive Maund – CliveMaund.com | |
![]() |
Chris Temple, Editor and Publisher – The National Investor |
![]() |
Dr. André Uddin – Research Capital Corporation |
1/17/2023 – Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study
1/17/2023 – Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
1/11/2023 – Algernon Pharmaceuticals Looks to Advance DMT Stroke Research
1/11/2023 – Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
1/10/2023 – Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil
1/9/2023 – Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil
1/4/2023 – Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program
1/3/2023 – Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
12/5/2022 – Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
11/16/2022 – Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.
Advancing new drug treatments for billion dollar global disease markets. | |
Conducting multiple phase II clinical trials | |
Experienced management team & globally recognized medical advisory board |
![]() Q2 2021 |
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
|
![]() Q4 2021 |
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
|
![]() Q4 2021 |
Phase 1 Study planned for DMT, Q4 2021
|